Can-Fite BioPharma to Discuss Namodenoson Cancer Data at Bio Europe
Ticker: CANF · Form: 6-K · Filed: Mar 11, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: partnership, licensing, oncology, conference
TL;DR
Can-Fite BioPharma is shopping Namodenoson for liver/pancreatic cancer at Bio Europe, looking for partners.
AI Summary
Can-Fite BioPharma Ltd. announced on March 11, 2024, that data regarding Namodenoson's treatment for pancreatic and liver cancer will be discussed at Bio Europe Conference partnering meetings. These discussions will focus on out-licensing and distribution opportunities for their drug.
Why It Matters
This filing indicates Can-Fite BioPharma is actively seeking partnerships to commercialize Namodenoson, potentially leading to wider patient access and revenue generation.
Risk Assessment
Risk Level: medium — The company is seeking out-licensing and distribution partners, which involves inherent risks in deal negotiations and market adoption.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Issuer of the filing and developer of Namodenoson.
- Namodenoson (drug) — Drug being discussed for pancreatic and liver cancer treatment.
- Bio Europe Conference (event) — Conference where partnering meetings will take place.
- March 11, 2024 (date) — Date of the press release and filing.
FAQ
What specific data will be discussed regarding Namodenoson?
The filing states that data concerning Namodenoson's treatment for pancreatic and liver cancer will be discussed, but does not provide specific details of the data itself.
What is the primary goal of the partnering meetings at Bio Europe?
The primary goal is to discuss out-licensing and distribution opportunities for Namodenoson.
Which types of cancer is Namodenoson being considered for?
Namodenoson is being discussed for the treatment of pancreatic and liver cancer.
When was the press release regarding these discussions issued?
The press release was issued on March 11, 2024.
What is the company's ticker symbol?
The filing does not explicitly state the ticker symbol, but the SEC file number is 001-36203.
Filing Stats: 208 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-03-11 07:27:14
Filing Documents
- ea0201517-6k_canfite.htm (6-K) — 10KB
- ea020151701ex99-1_canfite.htm (EX-99.1) — 11KB
- 0001213900-24-021223.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 11, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2